Dave Levitan

Long-term follow-up of a phase I and a phase II study shows that nivolumab produces strong overall survival benefit in patients with advanced renal cell carcinoma.

The MEK inhibitor binimetinib resulted in improved progression-free survival and response rates vs dacarbazine in patients with NRAS-mutated metastatic melanoma.

Patients with metastatic RCC who undergo cytoreductive nephrectomy plus targeted therapy have better survival over those treated only with targeted therapy.

Maintenance therapy with low-dose cyclophosphamide and methotrexate in women with hormone receptor-negative early breast cancer did not improve disease-free survival.

Patients with chronic myeloid leukemia who are treated with tyrosine kinase inhibitors could be at increased risk of long-term cardiovascular toxicity.

The USPSTF has issued an updated guideline with recommendations regarding screening for colorectal cancer. A systematic review found that screening can be of “substantial net benefit.”

Two studies show that early deep responses with TKIs yield lasting positive outcomes in CML patients, and that dasatinib outperforms imatinib.

A phase II trial showed that the tyrosine kinase inhibitor anlotinib has promising efficacy across a variety of subtypes of advanced refractory soft-tissue sarcoma.

The TKI brigatinib offered good response rates in a phase II trial of patients with ALK-positive non–small-cell lung cancer whose disease progressed on crizotinib.

Use of multiparametric MRI could allow a significant portion of men with elevated PSA levels to avoid undergoing a biopsy without missing clinically significant prostate cancers.

A hypofractionated shorter course of radiotherapy was not inferior to a conventional regimen in men with localized prostate cancer.

Alectinib yielded significantly prolonged progression-free survival compared with crizotinib in ALK-positive NSCLC patients, according to results of a Japanese open-label trial.

Cabazitaxel at two different doses was no better than docetaxel with regard to OS or PFS in men with metastatic castration-resistant prostate cancer.

The addition of docetaxel to ADT offered decreased QOL at 3 months vs ADT alone, but better QOL at 12 months, in metastatic hormone-sensitive prostate cancer.

An intermittent docetaxel regimen was non-inferior to continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer.

Testing for T790M mutations with plasma and urine assays can complement testing done from biopsy tissue in patients with EGFR TKI-resistant NSCLC.

The novel anti-PD-L1 agent avelumab showed some promising clinical activity and was generally well tolerated in a phase I trial of patients with unresectable, previously treated mesothelioma.

The multi-target RTK inhibitor anlotinib yielded a high response rate and was well tolerated in patients with advanced medullary thyroid carcinoma.

The addition of lenalidomide to cediranib failed to improve progression-free survival outcomes in patients with iodine 131–refractory differentiated thyroid cancer.

Testing for HPV infections in urine could be an extremely accurate way to exclude the possibility of such infections and screen for cervical cancer.

Radiotherapy delivered either pre- or postoperatively improved overall survival compared with surgery alone in patients with retroperitoneal sarcoma.

The incidence of cardiovascular events is reduced with increasing physical activity among women with nonmetastatic breast cancer.

Young adult female cancer survivors have unmet informational needs regarding reproductive issues and decisional conflict regarding fertility preservation.

A phase II trial found that cabozantinib offers significantly better progression-free survival over sunitinib in patients with untreated advanced RCC.

A new study has suggested two new ways to report on adverse events in the era of molecularly targeted therapies.

The use of ADT along with modern dose-escalated RT does not improve survival vs RT alone in men with favorable intermediate-risk prostate cancer.

The UK Lung Cancer Screening Trial found that a low-dose CT screening program targeting high-risk individuals can find lung cancer at early stages.

ASCO has released a clinical practice guideline on invasive cervical cancer. For the first time, ASCO created the guideline based on resource availability, tailoring recommendations to support basic- or limited-resource settings.

A 5-year analysis of the DASISION trial showed that dasatinib continued to offer better responses than imatinib in patients with chronic myeloid leukemia.

Twenty-five–year results of a Swedish study found that 2 years of adjuvant tamoxifen provides a long-term survival benefit in premenopausal women with estrogen receptor–positive breast cancer.